These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2024657)

  • 1. Clinical and histologic features of iron-related bone disease in dialysis patients.
    McCarthy JT; Hodgson SF; Fairbanks VF; Moyer TP
    Am J Kidney Dis; 1991 May; 17(5):551-61. PubMed ID: 2024657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine?
    Hodsman AB; Hood SA; Brown P; Cordy PE
    J Lab Clin Med; 1985 Dec; 106(6):674-81. PubMed ID: 4067379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated bone aluminum content in dialysis patients without osteomalacia.
    McCarthy JT; Kurtz SB; McCall JT
    Mayo Clin Proc; 1985 May; 60(5):315-20. PubMed ID: 3990380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low serum aluminum values in dialysis patients with increased bone aluminum levels.
    van Landeghem GF; D'Haese PC; Lamberts LV; Djukanovic L; Pejanovic S; Goodman WG; De Broe ME
    Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT; Milliner DS; Johnson WJ
    Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron overload and bone disease in chronic dialysis patients.
    Van de Vyver FL; Visser WJ; D'Haese PC; De Broe ME
    Nephrol Dial Transplant; 1990; 5(9):781-7. PubMed ID: 2129351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aluminum-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis.
    Smith AJ; Faugère MC; Abreo K; Fanti P; Julian B; Malluche HH
    Am J Nephrol; 1986; 6(4):275-83. PubMed ID: 3777036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron overload and bone disease in chronic dialysis patients.
    Van de Vyver FL; Visser WJ; D'Haese PC; De Broe ME
    Contrib Nephrol; 1988; 64():134-43. PubMed ID: 3180820
    [No Abstract]   [Full Text] [Related]  

  • 9. [A case of iron and aluminum related osteomalacia in a long-term hemodialysis patient].
    Yamagata K; Kobayashi M; Koyama A; Narita M; Amagai H; Ohno A; Yoshikawa S
    Nihon Jinzo Gakkai Shi; 1991 Apr; 33(4):437-42. PubMed ID: 1875564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum ferritin and tissue iron in anemic dialysis patients.
    Bárány P; Eriksson LC; Hultcrantz R; Pettersson E; Bergström J
    Miner Electrolyte Metab; 1997; 23(3-6):273-6. PubMed ID: 9387132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone aluminum and histomorphometric features of renal osteodystrophy.
    Hodsman AB; Sherrard DJ; Alfrey AC; Ott S; Brickman AS; Miller NL; Maloney NA; Coburn JW
    J Clin Endocrinol Metab; 1982 Mar; 54(3):539-46. PubMed ID: 7056841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aluminum and parathyroid hormone on osteoblasts and bone mineralization in chronic renal failure.
    Dunstan CR; Evans RA; Hills E; Wong SY; Alfrey AC
    Calcif Tissue Int; 1984 Mar; 36(2):133-8. PubMed ID: 6430496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum ferritin and bone marrow iron in patients undergoing continuous ambulatory peritoneal dialysis.
    Blumberg AB; Marti HR; Graber CG
    JAMA; 1983 Dec 23-30; 250(24):3317-9. PubMed ID: 6645029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aluminium-induced osteomalacia in severe chronic renal failure (SCRF).
    Visser WJ; Van de Vyver FL
    Clin Nephrol; 1985; 24 Suppl 1():S30-6. PubMed ID: 3915958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum ferritin in non-dialysis patients with chronic renal failure: relation to bone marrow iron stores.
    Milman N; Bangsbøll S; Pedersen NS; Visfeldt J
    Scand J Haematol; 1983 Apr; 30(4):337-44. PubMed ID: 6857149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sporadic aluminum osteomalacia: identification of patients at risk.
    Turner MW; Ardila M; Hutchinson T; Prichard S; Barré PE; Beauvais J; Kaye M
    Am J Kidney Dis; 1988 Jan; 11(1):51-6. PubMed ID: 3337100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aluminum poisoning].
    Cervar M; Stavljenic A; Vukicević S
    Lijec Vjesn; 1989; 111(4-5):164-9. PubMed ID: 2671563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone aluminum content in predialysis chronic renal failure and its relation with secondary hyperparathyroidism and 1,25(OH)2D3 treatment.
    Coen G; Mazzaferro S; Costantini S; Ballanti P; Carrieri MP; Giordano R; Smacchi A; Sardella D; Bonucci E; Taggi F
    Miner Electrolyte Metab; 1989; 15(5):295-302. PubMed ID: 2811788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The iron reserve status in patients on regular dialysis treatment].
    Zadrazil J; Papajík T; Scudla V; Jezáková J; Budíková M; Slavícek J
    Vnitr Lek; 1991 Apr; 37(4):369-75. PubMed ID: 2053308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of body iron stores on serum aluminum level in hemodialysis patients.
    Huang JY; Huang CC; Lim PS; Wu MS; Leu ML
    Nephron; 1992; 61(2):158-62. PubMed ID: 1630539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.